Compare Crispr Therapeutics AG (CRSP) vs GoPro Inc (GPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs GoPro Inc — how do they compare? Crispr Therapeutics AG trades at $53.95 (market cap $5.23B), while GoPro Inc trades at $0.58 (market cap $114.41M). The key difference: Crispr Therapeutics AG is far larger — about 45.7× GoPro Inc's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, GoPro Inc nearer its low. Which is the better fit depends on your goals.
| CRSP | GPRO | |
|---|---|---|
Market Cap | $5.23B | $114.41M |
Sector | Health | Technology |
52-Week High | $76.78 | $2.88 |
52-Week Low | $44.34 | $0.62 |
Enterprise Value | $3.65B | $173.19M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $54.02, up 0.95% on the day, with strong technical momentum and bullish moving average signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by CASGEVY sales expansion. Analyst sentiment remains positive with a $82.67 consensus price target representing 53% upside potential.
Despite promising pipeline developments and strong analyst support, CRSP faces significant fundamental challenges including negative profit margins, substantial cash burn, and high valuation multiples. The stock's near-term performance will depend on successful clinical trial outcomes and commercial execution of its gene-editing therapies.
GoPro (GPRO) trades at $0.58, down 17.87% amid ongoing financial challenges. The company reported Q2 2026 revenue of $105 million with negative earnings, continuing a trend of revenue decline from $1.1B in 2022 to $652M in 2025. Technical indicators show bearish momentum with RSI at oversold levels, while fundamentals reveal negative net income margins and cash flow concerns despite low valuation multiples.
The outlook remains highly speculative with a strategic sale process underway. Investment opportunity exists only for event-driven speculators betting on acquisition potential, while significant risks include going concern warnings, persistent cash burn, and competitive pressures in the action camera market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About GoPro Inc
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →
